Fibrocell Science, Inc. Inducted into Prestigious World Technology Network

Before you go, we thought you'd like these...
Before you go close icon

Fibrocell Science, Inc. Inducted into Prestigious World Technology Network

EXTON, Pa.--(BUSINESS WIRE)-- Fibrocell Science, Inc., an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, has been inducted into the distinguished World Technology Network (WTN) as a result of being named a finalist for the 2012 World Technology Award for Biotechnology.

Comprised of more than 1,000 members leading innovative advances in the fields of science and technology, the WTN presents its World Technology Awards each year to outstanding innovators from each sector within the technology arena.


Fibrocell Science, Inc. is at the forefront of cutting-edge research into the potential medical and aesthetic use of fibroblasts—skin cells responsible for the production of collagen and contribute to the formation of connective tissue fibers. The company recently launched LAVIV™ (azficel-T), the first and only personalized cell treatment approved by the FDA to improve the appearance of moderate to severe nasolabial folds or "smile line" wrinkles in adults.

"We are honored Fibrocell Science, Inc. was selected as a finalist for this notable award and has been inducted as a member of the World Technology Network," said David Pernock, Chairman and CEO of Fibrocell Science, Inc. "This acknowledgement highlights the innovative technology behind LAVIV, which isolates, purifies and multiplies a patient's own collagen producing fibroblast cells. Our vision is to develop and bring the value of these unique fibroblast cells to the medical and scientific community."

The WTN evaluated 23 companies for the Biotechnology Award including Genentech, GE, Complete Genomics and Harvard Bioscience. Fibrocell was named a finalist along with four other companies.

About The World Technology Awards

The World Technology Awards are presented each year to the outstanding innovators from each sector within the technology arena, both as a way to honor those individuals and as a vetting mechanism to determine the newest WTN members. The Awards are announced each year in a gala ceremony at the close of the annual World Technology Summit. The World Technology Summit is a global gathering of the WTN membership as well as other delegates.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (FCSC) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science, Inc. is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

About LAVIV™ (azficel-T)

LAVIV is indicated for use for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. The safety and efficacy of LAVIV for areas other than nasolabial folds have not been established; nor has the efficacy of LAVIV beyond six months been established. LAVIV is the first and only personalized cell treatment approved by the FDA for aesthetic use.

LAVIV is now available in major metropolitan areas throughout the U.S., exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science, Inc. on the treatment process. A list of trained and certified physicians is available at www.mylaviv.com and will be continually updated as new physicians are trained and begin offering LAVIV in their practice.

Important Safety Information About LAVIV™ (azficel-T)

LAVIV is made especially for you from your own skin cells. Using someone else's cells can cause a serious reaction. Do not let anyone else use your LAVIV. Prior to injection, confirm with your physician that your information on the LAVIV vial is correct. Your healthcare provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV. Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or COUMADIN® (warfarin sodium), keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. Tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse.

The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment. There are additional adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these adverse reactions. For more information about LAVIV, please see accompanying full Prescribing Information or visit www.mylaviv.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50453754〈=en



Media
Marina Maher Communications LLC
Heather Adamson, 212-485-6806
hadamson@mahercomm.com
or
Investors
ICR
Sherry Bertner, 646-277-1247
Sherry.Bertner@icrinc.com

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:

The article Fibrocell Science, Inc. Inducted into Prestigious World Technology Network originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners